2017
NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI
Soto H, Antonios J, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI. Neuro-Oncology 2017, 19: vi149-vi150. PMCID: PMC5692246, DOI: 10.1093/neuonc/nox168.611.Peer-Reviewed Original ResearchPD-1Dendritic cellsMAb blockadeContrast enhancementHost anti-tumor immune responseTreated with dendritic cellsAnti-tumor immune responseInflammatory responseClinical management of patientsDendritic cell vaccinesTumor-infiltrating lymphocytesSyngeneic immunocompetent miceTreated with immunotherapyCo-registration of PETSecondary lymphoid organsContrast-enhanced MRIManagement of patientsProbe uptakePET probeImmune inflammatory responseNon-invasive modalityNon-invasive imaging techniqueImmunocompetent micePre-contrast T1Cell vaccine
2014
IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA
Antonios J, Soto H, Harris R, Nathanson D, Sadeghi S, Ellingson B, Liau L, Prins R. IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA. Neuro-Oncology 2014, 16: v110-v110. PMCID: PMC4218227, DOI: 10.1093/neuonc/nou258.1.Peer-Reviewed Original ResearchProgrammed death-1Tumor-infiltrating lymphocytesPost-implant dayCombination groupPD-1Tumor microenvironmentLymph nodesTreatment groupsEffective anti-tumor immune responseFACS analysisAnti-tumor immune activityAnti-tumor immune responseIncreased tumor-infiltrating lymphocytesAnti-PD1 mAbNegative costimulatory moleculesPD-1 mAbDendritic cell vaccinesAnti-tumor responsesImmunocompetent C57BL/6 miceTumor-bearing hemisphereDecreased tumor volumeGL261 glioma cellsCombined treatment groupAntitumor responseDeath-1